Evommune, Inc. (EVMN) Balance Sheet
As of 2026-06-30 (10-Q), Evommune, Inc. (EVMN) reported total assets of $301.9M, total liabilities of $24.4M and shareholders' equity of $277.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $60.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EVMNEvommune, Inc.Follow EVMN — free
—
Price chart with a free account
- Market cap
- 185.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Dec, in 46 days
| Line | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|
| Cash and equivalents | 44.1 | 60.0 | |
| Short-term investments | 105.1 | 140.8 | |
| Current assets | 153.5 | 204.2 | |
| Total assets | 224.9 | 301.9 | |
| Current liabilities | 17.9 | 17.5 | |
| Total liabilities | 19.4 | 24.4 | |
| Shareholders' equity | 205.6 | 277.6 |
USD millions · SEC XBRL
Evommune, Inc. — questions
- How much cash does Evommune, Inc. have?
- $60.0M in cash and cash equivalents as of 2026-06-30.
- What are Evommune, Inc.'s total assets?
- $301.9M as of 2026-06-30.
- What is Evommune, Inc.'s shareholders' equity?
- $277.6M as of 2026-06-30.
Every figure on this page comes from Evommune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.